Go Deep
Kwality Pharmaceuticals Limited
Kwality Pharmaceuticals Limited Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 18,466 | 46.9 | 11.27 | 0.40 | 3,600.00 |
| Oct 2026 | 18,415 | 46.3 | 11.32 | 0.40 | 3,618.30 |
Kwality Pharmaceuticals Limited Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 1,623,522,000.0 | 1,571,136,000.0 | 1,234,397,000.0 | 1,110,510,000.0 |
| Net Profit | 256,245,000.0 | 253,010,000.0 | 160,096,000.0 | 141,161,000.0 |
| EPS | 24.7 | 24.4 | 15.4 | 13.6 |
Kwality Pharmaceuticals Limited Revenue & Profit: Last 5 Years
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Revenue | 5,030,590,000.0 | 3,701,970,000.0 | 3,070,769,000.0 | 2,510,300,000.0 | — |
| Net Profit | 673,463,000.0 | 398,451,000.0 | 237,962,000.0 | 193,724,000.0 | — |
| EPS | 64.9 | 38.4 | 22.9 | 18.7 | — |
Kwality Pharmaceuticals Limited Balance Sheet
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Total Assets | 5,922,091,000.0 | 4,472,716,000.0 | 3,942,097,000.0 | 3,536,317,000.0 | — |
| Total Liabilities | 2,622,882,000.0 | 1,848,757,000.0 | 1,716,262,000.0 | 1,545,626,000.0 | — |
| Total Equity | 3,315,956,000.0 | 2,640,483,000.0 | 2,242,114,000.0 | 2,005,165,000.0 | — |
Owes vs Owns
Kwality Pharmaceuticals Limited owed ₹0.44 for every ₹1 it owned in Mar 2026, up from ₹0.44 in Mar 2023.
| Period | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Owes vs Owns | 0.44× | 0.41× | 0.44× | 0.44× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Kwality Pharmaceuticals Limited Assets & Liabilities Breakdown (₹ Cr)
What it owns — Mar 2026
Cash & short-term investments 0.6%Receivables 47.3%Inventory 13.2%Fixed assets (tangible) 29.9%Intangible assets 1.0%Other assets 8.0%
How it's funded — Mar 2026
Short-term debt 17.1%Long-term debt 5.0%Payables 17.2%Other liabilities 5.1%Shareholders' equity 55.7%
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 3.6 | 14.8 | 5.9 | 7.4 |
| Receivables | 280.1 | 154.3 | 114.4 | 71.7 |
| Inventory | 78.3 | 83.5 | 78.4 | 86.3 |
| Fixed assets (tangible) | 176.9 | 155.5 | 150.4 | 144.7 |
| Intangible assets | 5.8 | 1.7 | 0.0 | 0.0 |
| Long-term investments | 0.0 | 0.0 | 0.0 | 0.0 |
| Other assets | 47.6 | 37.5 | 45.1 | 43.5 |
| Liabilities & equity | ||||
| Short-term debt | 101.1 | 97.3 | 78.6 | 63.0 |
| Long-term debt | 29.4 | 15.1 | 19.6 | 27.3 |
| Payables | 101.7 | 55.8 | 44.3 | 35.2 |
| Other liabilities | 30.1 | 16.6 | 29.2 | 29.1 |
| Shareholders' equity | 329.9 | 262.4 | 222.6 | 199.1 |
| Net tangible assets | 325.8 | 262.3 | 224.2 | 200.5 |
Kwality Pharmaceuticals Limited Cash Flow
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Operating Activities | 165,862,000.0 | 527,178,000.0 | 429,828,000.0 | 413,817,000.0 | — |
| Investing Activities | -349,096,000.0 | -285,152,000.0 | -263,966,000.0 | -484,408,000.0 | — |
| Financing Activities | 70,396,000.0 | -144,404,000.0 | -173,978,000.0 | 9,941,000.0 | — |